SANOFI-AVENTIS (EPA:SAN)

PRESS RELEASE

published on 09/27/2024 at 15:35, 1 year 4 months ago

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
US FDA approves Dupixent as the first-ever biologic medicine for COPD, based on phase 3 studies showing significant reduction in exacerbations and improved lung function. Dupixent is now leading in new-to-brand prescriptions for FDA-approved indications

FDA Approval Dupixent COPD Treatment Biologic Medicine Phase 3 Studies
BRIEF

published on 09/27/2024 at 13:05, 1 year 4 months ago

Dupixent Authorized in China as First Biologic Medicine for COPD Patients

China Approval COPD Dupixent Biologic Medicine
PRESS RELEASE

published on 09/27/2024 at 13:00, 1 year 4 months ago

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Dupixent approved in China as the first-ever biologic medicine for COPD patients, following landmark phase 3 studies. Approval crucial for addressing COPD burden in China

China COPD Dupixent Biologic Medicine Phase 3 Studies
BRIEF

published on 09/21/2024 at 00:41, 1 year 4 months ago

Sarclisa Approved in the United States for the Treatment of Multiple Myeloma

FDA Sanofi Multiple Myeloma Sarclisa First Line Treatment
BRIEF

published on 09/20/2024 at 13:50, 1 year 4 months ago

CHMP recommends approval of Dupixent for children aged 12 months and older

Children Medicine Dupixent CHMP Esophagitis
PRESS RELEASE

published on 09/20/2024 at 13:45, 1 year 4 months ago

Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old based on positive phase 3 study results. Dupixent would be the first medicine indicated for EoE in this age group

Children Dupixent CHMP EU Approval Eosinophilic Esophagitis
BRIEF

published on 09/20/2024 at 11:35, 1 year 4 months ago

Sanofi's Tolebrutinib Shows Promise in Delaying Disability Progression in MS

Multiple Sclerosis ECTRIMS 2024 Tolebrutinib HERCULES Study Disability Progression
PRESS RELEASE

published on 09/20/2024 at 11:30, 1 year 4 months ago

Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Study shows tolebrutinib delays disability progression in non-relapsing secondary progressive MS by 31%; global regulatory submissions in H2 2024. ECTRIMS 2024 data presented

ECTRIMS 2024 Tolebrutinib Disability Progression Secondary Progressive MS Global Regulatory Submissions
BRIEF

published on 09/16/2024 at 18:49, 1 year 4 months ago

Sanofi Reports Share and Voting Rights Data for August 2024

Voting Rights Shares Investor Relations Sanofi August 2024
PRESS RELEASE

published on 09/16/2024 at 18:44, 1 year 4 months ago

Sanofi: Information concerning the total number of voting rights and shares - August 2024
Sanofi discloses total number of voting rights and shares as per French Commercial Code and AMF regulations

Voting Rights French Commercial Code Shares AMF Regulations Sanofi

Published on 01/31/2026 at 03:15, 13 hours 16 minutes ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 14 hours 11 minutes ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 14 hours 51 minutes ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 16 hours 31 minutes ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 17 hours 31 minutes ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 15:54, 36 minutes ago

EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 4 hours 6 minutes ago

JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 13 hours 46 minutes ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 18 hours 31 minutes ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 20 hours 21 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026

View all EQS

Published on 01/30/2026 at 17:45, 22 hours 46 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 1 day 8 hours ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 1 day 22 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 1 day 22 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 1 day 22 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News